Bell CF, Ajmera M, Meyers J. Retrospective analysis of the burden of illness of eosinophilic granulomatosis with polyangiitis (EGPA) versus asthma in commercially insured US patients. Cureus J Med Science. 2023 Jul 21;15(7):e42241. doi: 10.7759/cureus.42241
Morris A, Samsell B, Dorsch K, McLean J, Moore M, Fox T, Roth C. Use of acellular dermal matrix for reconstruction of massive rotator cuff tears in an older population. Orthop Muscular Syst. 2018 Nov 1;7(4):1000261. doi: 10.4172/2161-0533.1000261
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.